The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Opdivo + Yervoy improves OS for advanced hepatocellular carcinoma in phase III trial

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Bristol Myers Squibb presented results from the phase III CheckMate-9DW trial evaluating the dual immunotherapy combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to investigator’s choice of lenvatinib or sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma. Results from the study were featured in a late-breaking oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Oncology providers, advocates form LGBTQ+ community group at ASCO with focus on research, education, equity

“When I joined ASCO in 2001, the most important thing to me was networking. I savored the opportunities to come to the annual meeting to meet and to talk with those who had led the studies that would inform standards of care, particularly in gynecologic oncology,” said Don S. Dizon. 
By Don S. Dizon, Chunkit Fung, Paula Chambers Raney, Charles Kamen and Shail Maingi
Clinical Roundup

Black patients who receive docetaxel for breast cancer experience less peripheral neuropathy than those who receive paclitaxel

Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center and the IU School of Medicine have discovered that Black patients with breast cancer who are treated with docetaxel experience less peripheral neuropathy. Their findings represent an important shift in knowledge about a patient population who’ve historically been underrepresented in breast cancer research.
Clinical Roundup

Sarclisa combination improves PFS in newly diagnosed transplant-ineligible MM in phase III trial

Data from the IMROZ phase III trial demonstrated Sarclisa (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone followed by Sarclisa-Rd (the IMROZ regimen) significantly reduced the risk of disease progression or death by 40%, compared to VRd followed by Rd in patients with newly diagnosed multiple myeloma not eligible for transplant. 
Table of Contents

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account